Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 125


Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors.

Shadrick WR, Slavish PJ, Chai SC, Waddell B, Connelly M, Low JA, Tallant C, Young BM, Bharatham N, Knapp S, Boyd VA, Morfouace M, Roussel MF, Chen T, Lee RE, Kiplin Guy R, Shelat AA, Potter PM.

Bioorg Med Chem. 2017 Nov 4. pii: S0968-0896(17)31594-8. doi: 10.1016/j.bmc.2017.10.042. [Epub ahead of print]


Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma.

Gutova M, Goldstein L, Metz M, Hovsepyan A, Tsurkan LG, Tirughana R, Tsaturyan L, Annala AJ, Synold TW, Wan Z, Seeger R, Anderson C, Moats RA, Potter PM, Aboody KS.

Mol Ther Oncolytics. 2016 Dec 14;4:67-76. doi: 10.1016/j.omto.2016.11.004. eCollection 2017 Mar 17.


Selective Inhibitors of Human Liver Carboxylesterase Based on a β-Lapachone Scaffold: Novel Reagents for Reaction Profiling.

Hatfield MJ, Chen J, Fratt EM, Chi L, Bollinger JC, Binder RJ, Bowling J, Hyatt JL, Scarborough J, Jeffries C, Potter PM.

J Med Chem. 2017 Feb 23;60(4):1568-1579. doi: 10.1021/acs.jmedchem.6b01849. Epub 2017 Feb 7.


Low-Temperature Catalytic Decomposition of 130 Tetra- to Octa-PCDD/Fs Congeners over CuOX and MnOX Modified V2O5/TiO2-CNTs with the Assistance of O3.

Zhao R, Jin D, Yang H, Lu S, Potter PM, Du C, Peng Y, Li X, Yan J.

Environ Sci Technol. 2016 Oct 7. [Epub ahead of print]


Tumour-selective targeting of drug metabolizing enzymes to treat metastatic cancer.

Wierdl M, Tsurkan L, Hatfield MJ, Potter PM.

Br J Pharmacol. 2016 Oct;173(19):2811-8. doi: 10.1111/bph.13553. Epub 2016 Aug 22. Review.


Carboxylesterases: General detoxifying enzymes.

Hatfield MJ, Umans RA, Hyatt JL, Edwards CC, Wierdl M, Tsurkan L, Taylor MR, Potter PM.

Chem Biol Interact. 2016 Nov 25;259(Pt B):327-331. doi: 10.1016/j.cbi.2016.02.011. Epub 2016 Feb 15. Review.


Contribution of aluminas and aluminosilicates to the formation of PCDD/Fs on fly ashes.

Potter PM, Dellinger B, Lomnicki SM.

Chemosphere. 2016 Feb;144:2421-6. doi: 10.1016/j.chemosphere.2015.11.009. Epub 2015 Nov 23.


Pharmacodynamic assays to facilitate preclinical and clinical development of pre-mRNA splicing modulatory drug candidates.

Shi Y, Joyner AS, Shadrick W, Palacios G, Lagisetti C, Potter PM, Sambucetti LC, Stamm S, Webb TR.

Pharmacol Res Perspect. 2015 Aug;3(4):e00158. doi: 10.1002/prp2.158. Epub 2015 Jun 26.


Targeting the DNA repair pathway in Ewing sarcoma.

Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, Miller GM, Caufield W, Freeman BB 3rd, Bahrami A, Pappo A, Wu J, Loh A, Karlström Å, Calabrese C, Gordon B, Tsurkan L, Hatfield MJ, Potter PM, Snyder SE, Thiagarajan S, Shirinifard A, Sablauer A, Shelat AA, Dyer MA.

Cell Rep. 2014 Nov 6;9(3):829-41. doi: 10.1016/j.celrep.2014.09.028. Epub 2014 Oct 23.


Sudemycin E influences alternative splicing and changes chromatin modifications.

Convertini P, Shen M, Potter PM, Palacios G, Lagisetti C, de la Grange P, Horbinski C, Fondufe-Mittendorf YN, Webb TR, Stamm S.

Nucleic Acids Res. 2014 Apr;42(8):4947-61. doi: 10.1093/nar/gku151. Epub 2014 Mar 11.


Targeting oxidative stress in embryonal rhabdomyosarcoma.

Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, Wu G, Bradley C, McEvoy J, Pappo A, Spunt S, Valentine MB, Valentine V, Krafcik F, Lang WH, Wierdl M, Tsurkan L, Tolleman V, Federico SM, Morton C, Lu C, Ding L, Easton J, Rusch M, Nagahawatte P, Wang J, Parker M, Wei L, Hedlund E, Finkelstein D, Edmonson M, Shurtleff S, Boggs K, Mulder H, Yergeau D, Skapek S, Hawkins DS, Ramirez N, Potter PM, Sandoval JA, Davidoff AM, Mardis ER, Wilson RK, Zhang J, Downing JR, Dyer MA; St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project.

Cancer Cell. 2013 Dec 9;24(6):710-24. doi: 10.1016/j.ccr.2013.11.002.


Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.

Metz MZ, Gutova M, Lacey SF, Abramyants Y, Vo T, Gilchrist M, Tirughana R, Ghoda LY, Barish ME, Brown CE, Najbauer J, Potter PM, Portnow J, Synold TW, Aboody KS.

Stem Cells Transl Med. 2013 Dec;2(12):983-92. doi: 10.5966/sctm.2012-0177. Epub 2013 Oct 28.


Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs.

Kasai K, Nakashima H, Liu F, Kerr S, Wang J, Phelps M, Potter PM, Goins WB, Fernandez SA, Chiocca EA.

Mol Ther Nucleic Acids. 2013 Aug 6;2:e113. doi: 10.1038/mtna.2013.38.


Control of RhoA methylation by carboxylesterase I.

Cushman I, Cushman SM, Potter PM, Casey PJ.

J Biol Chem. 2013 Jun 28;288(26):19177-83. doi: 10.1074/jbc.M113.467407. Epub 2013 May 8.


Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza ("Danshen").

Hatfield MJ, Tsurkan LG, Hyatt JL, Edwards CC, Lemoff A, Jeffries C, Yan B, Potter PM.

J Nat Prod. 2013 Jan 25;76(1):36-44. doi: 10.1021/np300628a. Epub 2013 Jan 3.


Fe2O3 nanoparticle mediated molecular growth and soot inception from the oxidative pyrolysis of 1-methylnaphthalene.

Herring MP, Potter PM, Wu H, Lomnicki S, Dellinger B.

Proc Combust Inst. 2013;34(1):1749-1757.


Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors.

Tsurkan LG, Hatfield MJ, Edwards CC, Hyatt JL, Potter PM.

Chem Biol Interact. 2013 Mar 25;203(1):226-30. doi: 10.1016/j.cbi.2012.10.018. Epub 2012 Nov 2.


Covalent inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by the carbamates JZL184 and URB597.

Crow JA, Bittles V, Borazjani A, Potter PM, Ross MK.

Biochem Pharmacol. 2012 Nov 1;84(9):1215-22. doi: 10.1016/j.bcp.2012.08.017. Epub 2012 Aug 27.


The development and application of small molecule modulators of SF3b as therapeutic agents for cancer.

Webb TR, Joyner AS, Potter PM.

Drug Discov Today. 2013 Jan;18(1-2):43-9. doi: 10.1016/j.drudis.2012.07.013. Epub 2012 Aug 3. Review.

Supplemental Content

Loading ...
Support Center